Literature DB >> 3316401

Preparation of 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate. An improved method.

M Koizumi1, K Endo, M Kunimatsu, H Sakahara, T Nakashima, Y Kawamura, Y Watanabe, Y Ohmomo, Y Arano, A Yokoyama.   

Abstract

Radionuclides or anti-cancer drugs may be coupled to antibodies for specific transport to target tissues. We have previously reported that several proteins could be rapidly and efficiently labeled with gallium (67Ga) by using deferoxamine (DFO) as a bifunctional chelating agent. In the present paper, we have described the use of hetero-bifunctional agents for the conjugation of DFO with antibodies and investigated the effect of coupling agents on in vitro properties and biodistribution of 67Ga-labeled antibodies. 67Ga-labeled monoclonal antibodies retained antigen-binding activity when prepared under optimum conditions. The use of hetero-bifunctional reagents, such as succinimidyl 6-maleimido-hexanoate (EMCS) or N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP), which link thioether bonds and disulfide bridges prevented the formation of polymerized antibodies. Although high non-specific uptake in the liver was observed with radiolabels prepared by the homo-bifunctional agent glutaraldehyde, uptake in the liver was low with conjugates linked by hetero-bifunctional agents. 67Ga-labeled antibodies with thioether bonds showed in vivo stability, but the clearance from the circulation was the fastest with the radiolabel holding disulfide bonds. The coupling reagents used to link DFO and antibodies greatly influenced both in vitro properties and in vivo distribution of labeled antibodies and 67Ga-labeled antibodies provide a good model for the study of coupling methods and biodistribution of antibody conjugates.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316401     DOI: 10.1016/0022-1759(87)90492-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

Review 1.  PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors:  Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2012-09-19       Impact factor: 2.408

Review 2.  (68)Ga-labeled radiopharmaceuticals for positron emission tomography.

Authors:  Dinesh Shetty; Yun-Sang Lee; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2010-10-12

Review 3.  Clinical applications of Gallium-68.

Authors:  Sangeeta Ray Banerjee; Martin G Pomper
Journal:  Appl Radiat Isot       Date:  2013-02-20       Impact factor: 1.513

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.